The global
human insulin market is expected to witness double digit growth during the
period 2015 to 2020 to reach $48,487.7 million value by 2020. The global human
insulin market is being driven by increasing prevalence of diabetic population,
and rise in aging population. Diabetes is a chronic and non-communicable
disease, and its global prevalence is increasing enormously. Rising prevalence
of obesity, rising awareness about diabetic care, and technological advancement
in insulin delivery devices are some of the factors driving the growth of the
global human insulin market. Growing demand of biosimilar drugs, due to its
cost effectiveness, pose an opportunity for the growth of the human insulin market.
In addition, increasing usage of insulin pens for the administration of insulin
helps to inject the accurate dose of insulin at
a time. However, high insulin analog cost and strict regulatory
requirements for approval of human insulin are inhibiting the growth of the
global human insulin market.
Request
for Report Sample: https://www.psmarketresearch.com/enquiry-form.php?enqid=176&title=Report%20sample
Increasing
prevalence of diabetes, increasing number of geriatric population, rising prevalence of obesity and increasing
R&D investment for more effective insulin are driving the growth of the
human insulin market in North America. The North American human
insulin market is expected to grow by a CAGR of 11.8% during the period 2015 to
2020. In Europe, according to International
Diabetic Federation in 2013, approximately 52 million people were suffering
from diabetes in Europe. The European human insulin market is expected to grow by a
CAGR of 12.6% during the period 2015 to 2020. Thus, increasing prevalence of
diabetes would increase the usage of human insulin. Also, in Asia Pacific
region, several
government initiatives are implemented to create awareness about prevention and
treatment of diabetes. The government is also taking initiatives to improve
healthcare infrastructure and provide treatment in rural areas. In
Asia-Pacific, the human insulin market is expected to witness CAGR of 13.9%
during the period 2015 to 2020.
Enquiry Before Buying: https://www.psmarketresearch.com/enquiry-form.php?enqid=176&title=Enquiry%20before%20purchase
The global human
insulin market has a fragmented structure with large number of companies
operating in the market. The key players in the human insulin market include Sanofi,
Novo Nordisk A/S, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer, Inc.,
Merck & Co., and Julphar.
Human Insulin Market Segmentation
Human Insulin Market by type
·
Traditional
human insulin
·
Modern
human insulin
Traditional Human
Insulin Market by type
·
Short
acting human insulin
·
Intermediate
acting human insulin
·
Premixed
human insulin
Modern Human Insulin Market
by type
·
Long
acting human insulin
·
Rapid
acting human insulin
·
Premixed
human insulin
Human Insulin Market by
Brand
·
Lantus
·
Novorapid
·
Humalog
·
Novomix
·
Levemir
·
Apidar
·
Humulin
·
Insuman
Geographical
Segmentation
Human Insulin Market by
Region
·
North
America
o
The
U.S.
o
Canada
·
Europe
o
Germany
o
France
o
The
U.K.
·
Asia-Pacific
o
India
o
China
o
Japan
·
Rest
of the World (ROW)
About
P&S Market Research
P&S Market
Research is a global market research and consulting company. We provide market
research reports, industry reports, business intelligence and research based
consulting services across a range of industries.
With the help
of our professional corporate relations with various companies, our market
research offers the most accurate market forecasting. Our analysts and
consultants interact with leading companies of the concerned domain to
substantiate every single data presented in our publication. Our research assists our client in identifying
new and different windows of opportunity and frame informed and customized
strategies for expansion in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY -10016
Toll-free: +1-888-778-7886
(USA/Canada)
